Skip to content

Faiez M. Zannad

Inserm

6 papers in the Anchorcite directory, published between 1999 and 2021, cited 44,582 times in total.

ORCID profile

Research topics

Frequent co-authors

Papers

  1. 2013 ESH/ESC Guidelines for the management of arterial hypertensionEuropean Heart Journal · 2013 · 13,739 citations

    The ESH/ESC Guidelines represent the views of the ESH and ESC and were arrived at after careful consideration of the available evidence at the time they were written.Health professionals are encouraged to take them fully into account when exercising their…

  2. The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart FailureNew England Journal of Medicine · 1999 · 9,307 citations

    BACKGROUND AND METHODS: Aldosterone is important in the pathophysiology of heart failure. In a doubleblind study, we enrolled 1663 patients who had severe heart failure and a left ventricular ejection fraction of no more than 35 percent and who were…

  3. 2013 ESH/ESC Guidelines for the management of arterial hypertensionJournal of Hypertension · 2013 · 5,764 citations

    Table of Contents Introduction Principles New aspects Epidemiological aspects Relationship of blood pressure to cardiovascular and renal damage Definition and classification of hypertension Prevalence of hypertension Hypertension and total cardiovascular risk Assessment of total cardiovascular risk Limitations Summary of recommendations…

  4. Cardiovascular and Renal Outcomes with Empagliflozin in Heart FailureNew England Journal of Medicine · 2020 · 5,468 citations

    BACKGROUNDSodium-glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of hospitalization for heart failure in patients regardless of the presence or absence of diabetes.More evidence is needed regarding the effects of these drugs in patients across the broad spectrum of heart…

  5. Empagliflozin in Heart Failure with a Preserved Ejection FractionNew England Journal of Medicine · 2021 · 5,211 citations

    BACKGROUND: Sodium-glucose cotransporter 2 inhibitors reduce the risk of hospitalization for heart failure in patients with heart failure and a reduced ejection fraction, but their effects in patients with heart failure and a preserved ejection fraction are uncertain. METHODS: In…

  6. Eplerenone, a Selective Aldosterone Blocker, in Patients with Left Ventricular Dysfunction after Myocardial InfarctionNew England Journal of Medicine · 2003 · 5,093 citations

    BACKGROUND: Aldosterone blockade reduces mortality and morbidity among patients with severe heart failure. We conducted a double-blind, placebo-controlled study evaluating the effect of eplerenone, a selective aldosterone blocker, on morbidity and mortality among patients with acute myocardial infarction complicated by…

Metadata from OpenAlex (CC0).